Supplementation With Alpha-lipoic Acid and Silybum Marianum(LUDLEV®) for the Improvement of Fatty Liver Disease

Inclusion Criteria: * Subjects treated at the Instituto de Investigaciones Médico Biológicas de la Universidad Veracruzana with a diagnosis of Fatty Liver Disease * Agree to voluntarily participate in the study and sign informed consent. * Patients with evidence of hepatic steatosis who are overweight or obese * Patients with evidence of hepatic steatosis with diabetes mellitus and overweight or obesity. * Patients with evidence of steatosis plus metabolic risk abnormalities will be included (waist circumference \>102 in men, 88 cm in women, blood pressure \>130/85 mmHg or specific treatment, triglycerides \>150 mg/dL or specific treatment, HDL cholesterol \< 40 mg/dL in men, \<50 mg/dL in women or specific treatment, HOMA-IR \>2.5, CRP \>2 mg/L or prediabetes defined by fasting glucose detection 100 to 125 mg/dL, postload glucose 2 hours 140 to 199 mg/dL or HbA1c between 5.7 to 6.4%) * Accept not to start any diet program during the study period. * Agree not to change your current exercise plan during the study period Exclusion Criteria: * Patients meeting diagnostic criteria for Fatty Liver Disease with normal weight * Patients with terminal illness, cancer, renal disease in renal replacement therapy * Pregnant women * Patients with inability to understand or follow the study protocol * Sensitivity to the components of the formula.